Skip to main content
. 2020 May 28;2(1):vdaa064. doi: 10.1093/noajnl/vdaa064

Figure 1.

Figure 1.

Cumulative incidence of BMs. EGFR-mt patients developed BMs more quickly, and the rate of BMs reached about 50%, while the rate for EGFR-wt patients was about 30% (P < .001, log-rank test). Almost 80% of patients developed BMs within 2–3 years following the diagnosis of NSCLC. EGFR, epidermal growth factor receptor; mt, mutated; wt, wild type; BMs, brain metastases.